Viridian Shares Jump on Positive Eye Disease Trial Results
Viridian Therapeutics shares rose 35 percent after its drug elegrobart met late-stage trial goals for thyroid eye disease. The study showed significant improvements in eye bulging and double vision for chronic patients.
Xurve View
Insights:
Xurve View
VIRIDIAN THERAPEUTICS INC shares rose 35% Tuesday afternoon after its experimental drug elegrobart met the primary goal in a late-stage trial. The trial focused on chronic thyroid eye disease (TED) patients, following a previous study in March that triggered a sell-off. Success in this chronic population positions Viridian to compete in a market RBC Capital Markets estimates at $1 billion.
